Weiss Ratings Reiterates Sell (E+) Rating for Drugs Made In America Acquisition (NASDAQ:DMAA)

Key Points

• Weiss Ratings has reiterated a "sell (E+)" rating for Drugs Made In America Acquisition (NASDAQ:DMAA), indicating ongoing negative sentiment from investment analysts.
• The stock opened at $10.33 on Friday, with a 52-week range between $9.95 and $10.34.
• Recent activity shows several institutional investors have acquired stakes in DMAA, with notable investments from Shaolin Capital Management and Boothbay Fund Management during the second quarter.

Drugs Made In America Acquisition (NASDAQ:DMAA - Get Free Report)'s stock had its "sell (e+)" rating restated by investment analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

Drugs Made In America Acquisition Stock Performance

DMAA stock opened at $10.33 on Friday. The company has a 50-day simple moving average of $10.28. Drugs Made In America Acquisition has a 52 week low of $9.95 and a 52 week high of $10.34.

Institutional Investors Weigh In On Drugs Made In America Acquisition

Institutional investors and hedge funds have recently bought and sold shares of the company. Shaolin Capital Management LLC bought a new stake in Drugs Made In America Acquisition during the second quarter worth about $1,020,000. Clear Street LLC bought a new stake in Drugs Made In America Acquisition during the second quarter worth about $1,149,000. Radcliffe Capital Management L.P. bought a new stake in Drugs Made In America Acquisition during the second quarter worth about $1,293,000. Mizuho Securities USA LLC bought a new stake in Drugs Made In America Acquisition during the first quarter worth about $5,402,000. Finally, Boothbay Fund Management LLC bought a new stake in Drugs Made In America Acquisition during the second quarter worth about $5,814,000.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.